Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.
about
Advanced techniques using contrast media in neuroimagingHigh-grade glioma management and response assessment-recent advances and current challengesMalignant gliomas: current perspectives in diagnosis, treatment, and early response assessment using advanced quantitative imaging methodsPerfusion MRI: the five most frequently asked clinical questions.Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab.MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-grade gliomas.Cerebral radiation necrosis.Low incidence of pseudoprogression by imaging in newly diagnosed glioblastoma patients treated with cediranib in combination with chemoradiation.The diagnosis and treatment of pseudoprogression, radiation necrosis and brain tumor recurrenceAdvanced magnetic resonance imaging of the physical processes in human glioblastoma.Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomasApplication of iron oxide nanoparticles in glioma imaging and therapy: from bench to bedside.Detecting tumor progression in glioma: Current standards and new techniques.Advanced imaging techniques in brain tumors.Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma.¹⁸F-FLT and ¹⁸F-FDOPA PET kinetics in recurrent brain tumorsQuantitative multiparametric MRI assessment of glioma response to radiotherapy in a rat modelPerfusion and permeability MR imaging of gliomas.Advances in MRI assessment of gliomas and response to anti-VEGF therapy.Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma.Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.MR imaging of neoplastic central nervous system lesions: review and recommendations for current practice.Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide.Assessment of MRI parameters as imaging biomarkers for radiation necrosis in the rat brain.Neuroimaging findings of the post-treatment effects of radiation and chemotherapy of malignant primary glial neoplasmsDifferentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides.Usefulness of MS-MLPA for detection of MGMT promoter methylation in the evaluation of pseudoprogression in glioblastoma patients.Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumabPost-treatment imaging of high-grade gliomasReevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survivalSpecific chemotaxis of magnetically labeled mesenchymal stem cells: implications for MRI of gliomaAssociation of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials.Detection of glioblastoma response to temozolomide combined with bevacizumab based on μMRI and μPET imaging reveals [18F]-fluoro-L-thymidine as an early and robust predictive marker for treatment efficacy.MRI perfusion in determining pseudoprogression in patients with glioblastoma.From patient-specific mathematical neuro-oncology to precision medicineEarly post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader StudySerial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.Subcurative radiation significantly increases cell proliferation, invasion, and migration of primary glioblastoma multiforme in vivo.Circulating tumor cell is a common property of brain glioma and promotes the monitoring system
P2860
Q22252349-0ECA9DEF-4F76-4299-988C-195CDC52B029Q26740664-02E68BD8-260A-468F-AD7B-54D48CC29340Q26853516-94AB6ED3-AA06-4E44-A102-9083E4C01391Q30416198-FBDF789F-B136-4F96-ABC0-042ED5F5A5E0Q30429169-6F8EE937-9DBC-478D-A9F5-6C3EEAC6FEAFQ30636257-4D00E5C1-538B-456A-ABD7-6C60007E0369Q30686634-47E3F9B9-E3C6-4476-BB64-1F805BBF3B70Q30708866-C8C6A2D7-2FAE-4C82-94E0-123EE041A825Q30835167-BD47745D-AAC0-4DC4-BAC5-5716D0D452CCQ30847284-C1C1978B-B447-4531-854E-CC761059202BQ30937034-2038F69F-3A5D-4135-82D6-7F3A978E74FBQ31038332-C4B59239-3C79-43A0-A921-FAD574D6259CQ31065446-4DB53868-28FD-4549-91D3-6596B2244954Q31132701-B7FC4096-1B68-4E0D-94E9-6E0D7DB5762DQ33517391-E8D08B6B-0B31-4E96-83C2-E29F88CD3377Q33549622-292A826C-0266-405A-93BD-A5AB5AF1B152Q33560943-B4D74764-46EF-4DF1-94DA-E22032DD102AQ33616603-F330AF4B-73AB-4F52-B02C-7A773B924058Q33788231-4E2974F9-4F97-455F-A4E3-DFBC1E1DC311Q33793253-479EE2F3-1AD6-4943-9800-F2082B1B4826Q33843085-04DAF208-F7CB-4216-B40A-524F12E8F5E0Q33894461-1117F868-EE14-4DD2-9C9F-74DC061AEC65Q34053148-A9E92978-B39B-48E0-A74B-9C65E52C5E82Q34132767-741E5275-622B-4EC6-992A-5C6211B17127Q34224128-27A8CED8-734A-46E7-919D-4493269DB1A5Q34369465-A7DF6DB7-6B17-4164-BAB4-272F73365739Q34681190-8D0D06CA-8D87-4ABC-AE6C-8DA36E2DA0F9Q34722521-B3E9200C-0959-4690-97A3-AECFB1F2EAAFQ35028897-201B7A83-A3B8-435C-9C6A-7EF8D0B8CA89Q35568711-47608D24-4EF2-48A5-8DE6-7002BD79EBDAQ36048166-E7500F9A-81F7-4BFE-86F8-02DC06A2EED7Q36071865-A5EDCDAC-D94E-42F9-9DEA-F8CFC6DADF26Q36427538-45696678-7126-4CC6-985D-422F3C111524Q36500372-5D91C049-61EE-45FC-8244-37B0C75298CAQ36585386-5420ED16-0DF4-4DB4-87A6-4DCD19C68C4CQ36733380-A766C57E-75D2-4A8B-8223-78F089CF4A45Q36943907-CEFEA1D4-03FE-475F-9375-A323FD470FA3Q37348479-2F5F15FA-01CF-4A13-B648-B8E57FDB43D0Q37664046-A1096D4A-7954-4C6F-B588-08EEDA9BEC3EQ37687613-78FB7815-78B2-4072-9559-4DB6B4248265
P2860
Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.
description
2009 nî lūn-bûn
@nan
2009 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.
@ast
Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.
@en
type
label
Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.
@ast
Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.
@en
prefLabel
Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.
@ast
Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.
@en
P1476
Pseudoprogression and pseudoresponse: challenges in brain tumor imaging.
@en
P2093
Jennifer L Clarke
Susan Chang
P2888
P304
P356
10.1007/S11910-009-0035-4
P577
2009-05-01T00:00:00Z
P6179
1052174107